Publications by authors named "M Wagenmann"
Article Synopsis
- Targeted therapies using biologics for atopic diseases, urticaria, and angioedema are advancing quickly, with several new antibodies developed, tested, and approved for clinical use, like omalizumab and dupilumab.
- There is ongoing research into combining different biologics for enhanced treatment efficacy, expanding their applications to conditions like food allergies and eosinophilic esophagitis.
- There are emerging concerns about unexpected side effects and hypersensitivity reactions associated with these therapies, raising important questions about their safety and mechanisms, particularly in specific patient groups like children.
Using patient-generated health data more efficient and effectively to facilitate the implementation of value-based healthcare in the EU - Innovation report.
Comput Struct Biotechnol J
December 2024
Healthcare services and products are rapidly changing due to the development of new technologies, offering relevant solutions to improve patient outcomes. Patient-Generated Health Data and knowledge-sharing across the European Union (EU) has a great potential of making healthcare provision more effective and efficient by putting the patient at the centre of the healthcare process. While such initiatives have been taken before, a uniting and overarching approach is still missing.
View Article and Find Full Text PDFArticle Synopsis
- Pivotal studies have shown that dupilumab significantly improves nasal polyp scores, symptom scores, and overall quality of life in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
- A large-scale evaluation at six European centers found that after 24 and 52 weeks of treatment, patient outcomes consistently improved, regardless of demographic factors or prior treatments.
- By the end of the study, a substantial percentage of the patients met improved health criteria, indicating that dupilumab remains effective over time and not influenced by previous sinus surgeries or other major health issues.
Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison.
J Allergy Clin Immunol Pract
December 2024
Background: Dupilumab and mepolizumab have shown efficacy and safety in treating chronic rhinosinusitis with nasal polyps (CRSwNP).
Objective: Without available results from head-to-head randomized control trials (RCTs) comparing dupilumab with other biologics, we conducted an indirect treatment comparison (ITC) with mepolizumab.
Methods: A systematic literature review identified RCTs of biologics in CRSwNP.